MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2023 International Congress

August 27-31, 2023. Copenhagen, Denmark.

View by Title View Categories
Jump to:  View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z
  • D-penicillamine induced myasthenia gravis – the possible complication of Wilson’s disease treatment.

    A. Antos, T. Litwin, J. Bembenek, M. Skowrońska, I. Kurkowska-Jastrzębska, A. Członkowska (Warsaw, Poland)

  • Dance for Parkinson’s disease to improve gait and balance: clinical assessments vs. objective measures.

    HHN. Kalyani, K. Sullivan, G. Moyle, S. Brauer, E. Jeffrey, G. Kerr (Colombo, Sri Lanka)

  • DaT Scan Positive Parkinson’s Disease in a Patient with Anti-MuSK Positive Myasthenia Gravis

    G. Andraos, N. Ahmed, V. Veerappan (Greer, USA)

  • DaT-Scans Have Limited Utility in Predicting Treatment Response to Ventriculoperitoneal Shunts in Normal Pressure Hydrocephalus

    J. Ma, M. Hamed, D. Victor, T. Kay, M. Salgado (Brooklyn, USA)

  • Data-driven Clustering of Neurodegenerative diseases based on EEG Spectrum power-law decay: the DaCNES Study.

    G. Mostile, R. Terranova, G. Carlentini, C. Terravecchia, G. Donzuso, G. Sciacca, C. Cicero, A. Luca, A. Nicoletti, M. Zappia (Catania, Italy)

  • Data-driven subtypes of multiple system atrophy and the implication on prognosis

    C-C. Fan, C. Han, X-M. Wang, W. Mao, E-H. Xu, P. Chan, S-Y. Liu (Beijing, China)

  • DBS and neck muscle vibration shift impaired pallidal multifractal complexity towards the normal state in dystonia patients

    U. Semenova, A. Tomskiy, I. Dzhalagoniya, A. Sedov (Moscow, Russian Federation)

  • Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial

    O. Rascol, F. Ory-Magne, JP. Azulay, L. Defebvre, JL. Houeto, D. Maltete, P. Remy, A. Foubert-Samier, A. Sommet, C. Thalamas, S. Thobois, JC. Corvol, N. Ns-Park/fcrin (Toulouse, France)

  • Decreased α-synuclein membrane-binding in the enteric nervous system as a marker of early pathology in Parkinson’s disease

    V. Gao, J. Briano, L. Komer, C. Crawford, C. Henchcliffe, A. Lee, J. Burré (Brooklyn, USA)

  • Deep brain stimulation and fusion technologies: a synthesis study

    V. Rama Raju (Hyderabad, India)

  • Deep Brain Stimulation Duration and Changes in Basal Ganglia Excitatory/Inhibitory Balance in Children and Young Adults with Dystonia

    T. Larsh, D. Gilbert, S. Vadivelu, S. Wu (Cincinnati, USA)

  • Deep brain stimulation enhances movement velocity during spiral drawing in Parkinson’s disease

    G. Gonzalez-Escamilla, M. Bange, D. Herz, G. Tinkhauser, M. Glaser, C. Ciolac, H. T, P. Brown, S. Groppa (Mainz, Germany)

  • Deep brain stimulation for advanced Parkinson’s disease: Initial experience in Varna, Bulgaria

    M. Tsalta-Mladenov, V. Dimitrova, M. Moynov, Y. Enchev, S. Andonova (Varna, Bulgaria)

  • Deep brain stimulation for movement disorders: Assessing disparities in access to care

    Z. Rifi, M. Harary, L. Remore, K. Fu, A. Bari (Los Angeles, USA)

  • Deep Brain Stimulation for Multiple Sclerosis Tremors: A Case Series

    P. Gyawali, F. Farrokhi, M. Marsans, J. Roberts (Seattle, USA)

  • Deep Brain Stimulation for Orthostatic Tremor: An observational study’

    W. Babeliowsky, M. Bot, W. Potters, P. Vanden Munckhof, E. Blok, R. de Bie, P. Schuurman, AF. van Rootselaar (Amsterdam, Netherlands)

  • Deep brain stimulation for the management of movement disorders in Rett syndrome

    M. Hull, D. Curry, M. Parnes (Houston, USA)

  • Deep brain stimulation impacts functional brain connectivity in Parkinson’s disease.

    R. Jech, F. Ruzicka, D. Kiakou, A. Lasica, P. Filip, K. Burdova, D. Urgosik, K. Mueller (Prague, Czech Republic)

  • Deep brain stimulation in chorea: four cases and literature review

    M. Hull, M. Parnes, A. Tarakad (Houston, USA)

  • Deep Brain Stimulation in Parkinson’s Disease Patients: A One Year Follow-up in the Understudied Geography of Brazil

    M. Faria, A. Novicki, F. Godinho, Y. Souza, J. Woods, K. Stromberg, R. Paolillo, C. Rocha (Belo Horizonte, Brazil)

  • Deep Brain Stimulation in Parkinson’s Disease: real-world outcomes at a single centre

    B. Lonergan, M. Ciocca, A. Bocum, D. Nandi, P. Bain, G. Charlesworth, N. Pavese, Y. Tai (London, United Kingdom)

  • Deep brain stimulation modulates subthalamic beta bursts related to movement velocity adjustments in Parkinson’s disease

    M. Bange, G. Gonzalez-Escamilla, DM. Herz, G. Tinkhauser, M. Glaser, D. Ciolac, H. Tan, P. Brown, S. Groppa (Mainz, Germany)

  • Deep Brain Stimulation Outcomes in Underreported Dystonias: A Case Series

    B. Dahlben, N. Bukhari-Parlakturk, DA. Turner, S. Harward, D. Southwell, KT. Mitchell (Durham, USA)

  • Defining neuropsychiatric symptoms fluctuations in Parkinson’s disease

    A. Trinchillo, FP. Cucinotta, A. de Angelis, I. Cociasu, M. Horne, F. Morgante, L. Ricciardi (Giugliano in Campania, Italy)

  • Delayed Diagnosis of Hyperthyroidism in Parkinson’s Disease Patient: A Case Report

    MH. Utami, A. Tiksnadi, D. Tunjungsari (Jakarta, Indonesia)

  • Delta(0.5-2Hz) Spectral Power reduction in the frontal region in NREM Sleep are Associated with dyskinesia in Parkinson’s Disease

    CJ. Mao, YM. Wang, F. Wang, CK. Zhong, S. Zhuang, XY. Cheng, JY. Liu, CF. Liu (Suzhou, China)

  • Demographic, clinical and genetic factors affecting amantadine response among patients with Parkinson disease

    J. Yu, L. Saadatpour, H. Kaur, I. Mata, H. Fernandez (Cleveland, USA)

  • Depression and Activities of Daily Living in Idiopathic Parkinson’s Disease without Dementia.

    L. Ortega, C. González, S. Otalvaro, J. Ayala (Cali, Colombia)

  • Depression in Parkinson’s disease is associated with subcortical neurodegeneration and increased risk of all-cause mortality and dementia

    J. Badenoch, A. Paris, B. Jacobs, A. Noyce, C. Marshall, S. Waters (London, United Kingdom)

  • Depression profile in Mexican patients with Parkinson Disease: a cross-sectional study

    P. Reyes-Pérez, A. Medina-Rivera, A. Ruiz-Contreras, S. Alcauter-Solorzano, M. Rentería, A. Lazaro-Figueroa, Y. Matuk-Pérez, N. Gandarilla-Martínez, K. Salinas-Barboza, I. Estrada-Bellmann (Queretaro, Mexico)

  • Describing the syndrome: a comprehensive analysis of a large cohort of corticobasal syndrome with pathological correlation

    D. Vaughan, M. Theilmann Jensen, D. Lux, L. Wu, Z. Jaunmuktane, T. Revesz, T. Lynch, M. Stamelou, K. Seppi, R. Vandenberghe, T. Warner, K. Bhatia, A. Lees, A. Church, N. Leigh, P. Taba, T. Matsalu, P. Mir, B. Ghosh, M. Picillo, J. Wallin, P. Svenningsson, Y. Compta, J. Rohrer, J. Rowe, H. Morris (London, United Kingdom)

  • Description of a series of GAA-FGF14 ataxia / SCA27b patients

    P. Iruzubieta, D. Pellerin, J. Ruiz, A. Bergareche, E. Mondragon, I. Albajar, J. Equiza, G. Nuñez, P. Arratibel, F. Moreno, J. Poza, M. Ruibal, R. Fernández-Torrón, A. Vinagre, I. Croitoru, M. Dicaire, B. Brais, H. Houlden, A. Lopez Munain (San Sebastián, Spain)

  • Design of a Phase 2 Study of Suvecaltamide in Moderate to Severe Parkinson’s Disease Tremor

    R. Hauser, C. Adler, G. Deuschl, M. Baladi, P. Chandler, T. Skarpass, K. Xu, P. Lewitt (Tampa, USA)

  • Design of a time-to-event study in GBA Parkinson’s Disease patients: Efficacy and safety of BIA 28-6156, an allosteric activator of beta-glucocerobridase (GCase)

    L. Magalhães, M. Fonseca, G. Castilla-Fernández, R. Costa, D. Simon, J. Holenz, N. Mendonça (Coronado, Portugal)

  • Detailed illustration of a Turkish patient with homozygous C19ORF12 mutation

    H. Onder, T. Comoglu, S. Comoglu (Ankara, Turkey)

  • Detecting Changes in Parkinson’s Motor Symptom Patterns Using Wearable Devices

    A. Arnold, A. Hare, W. Chen, T. Jansen, R. Gilron (San Francsico, USA)

  • Detecting clinical fluctuations in chronic biomarker recordings: experiences with chronic subthalamic peak beta band recordings in a large Parkinson’s disease patient cohort

    LK. Feldmann, J. Habets, V. D'Onofrio, V. Mathiopoulou, J. Busch, K. Faust, GH. Schneider, D. Gruber, G. Ebersbacher, AA. Kühn (Berlin, Germany)

  • Detection and classification of GBA variants PD-related: is there sex unbalance?

    C. Reale, C. Panteghini, I. Colangelo, M. Suerz, R. Cilia, R. Eleopra, B. Garavaglia, F. Invernizzi (Milan, Italy)

  • Detection of Camptocormia Using Ultrasound in Parkinson’s Disease

    R. Yilmaz, R. Wolke, N. Puls, M. Sorgun, G. Deuschl, D. Berg, N. Margraf (Ankara, Turkey)

  • Detection of freezing of gait in people with Parkinson’s disease using novel deep learning approaches.

    EC. Klaver, IB. Heijink, G. Silvestri, JPP. van Vugt, J. Nonnekes, RJA. van Wezel, MC. Tjepkema-Cloostermans (Nijmegen, Netherlands)

  • Detection of Levodopa induced Dyskinesia based on spectral features from subthalamic-LFP and sensorimotor-ECoG

    J. Habets, R. Lofredi, J. Busch, V. Mathiopoulou, J. Roediger, R. Koehler, J. Vanhoecke, P. Krause, K. Faust, GH. Schneider, WJ. Neumann, A. Kühn (Berlin, Germany)

  • Determinants of care partner burden in atypical parkinsonian syndromes

    M. Ivancic, J. Shurer, M. Schmidt, V. Nesspor, M. Li, Y. Lin, R. Xu, G. Schumock, M. Sklerov, A. Pantelyat (Chapel Hill, USA)

  • Determinants of quality of life and daily mobility in Parkinson’s disease: the role of fear of falling.

    A. Magliozzi, V. Pozzilli, G. Sergi, V. Di Lazzaro, M. Marano (Roma, Italy)

  • Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia

    E. Kim, J. Shaqfah, I. Frouni, P. Huot (Montreal, Canada)

  • Developement and acceptability testing of a patient decision aid on levodopa/carbidopa intestinal gel.

    C-C. Cayer, IBB. Beaulieu-Boire, A-T. Tanguay (Sherbrooke, Canada)

  • Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)

    M. Tosin, T. Mestre, G. Stebbins, G. Mangone, S. Videmsky, S. Ali, D. Aarsland, J. Goldman, T. Khoo, S. Lewis, P. Martinez-Martin, O. Ojo, J. Pagonabarraga, A. Schrag, D. Weintraub, C. Goetz (Chicago, USA)

  • Development and Evaluation of a Digital Resource Library for Arkansans with Parkinson Disease and Their Caregivers

    S. Dhall, A. Diamond, T. Virmani, R. Sloan, T. Burrow, J. Chacko, C. Fullen, T. Reckling, J. Holton, H. Pickett, H. Petersen, K. Coleman, D. Mcclendon, D. Chandler, E. Echols, C. Gauss, K. Donovan, S. Parveen, R. Dhall (Little Rock, USA)

  • Development and preliminary results of a new picture-based self-rating tool for neuropsychiatric syndromes in Parkinson’s disease

    S. Simon, JC. Baldermann, K. Böttcher, S. Meißner, C. Schedlich-Teufer, D. Gruber, D. Podes, LS. Neumaier, E. Kalbe, GR. Fink, G. Ebersbach, W. Jost, M. Barbe, J. Kessler, ST. Jost (Cologne, Germany)

  • Development and quantified evaluation of a continuous smartphone app-based monitoring approach to individualize Parkinson’s disease management.

    F. Thieken, S. Wattendorf, P. Korn, M. Kontz, O. Ataiy, P. Fischer, MO. Ashraf, V. Gross, D. Pedrosa, K. Sohrabi, L. Timmermann (Marburg, Germany)

  • Development and validation of a new wearable device for the differential diagnosis of resting tremor

    M. de Maria, F. Aracri, C. Calomino, M. Crasà, J. Buonocore, B. Vescio, A. Quattrone (Catanzaro, Italy)

  • Development and Validation of an Algorithm to Automatically Assess Motor Symptoms of Parkinson’s Disease

    S. Sekimoto, G. Oyama, Y. Nonomiya, T. Hayashi, M. Soshi, S. Chiba, N. Hattori (Bunkyo-ku, Japan)

  • Development of a health-related quality-of-life (HR-QoL) questionnaire for hereditary spastic paraplegia (HSP) patients and caregivers.

    J. Malina, E-M. Hüßler, B. Schröder, N. Wiesenberg, T. Kühl, S. Klebe (Essen, Germany)

  • Development of a patient journey map for people living with Parkinson’s disease

    A. Albanese, R. Case, A. Amit, S. Ben-Hamo (Milan, Italy)

  • Development of a Vibro-Tactile Stimulation wristband for targeted therapy of Focal Task Specific Dystonias

    S. Arjun, A. Singh, H. Singh, R. Jain, I. Ahuja (Chandigarh, India)

  • Development of an Item Bank for Assessing Psychosis in Parkinson’s Disease: A Systematic Review

    G. Mangone, M. Tosin, C. Goetz, G. Stebbins, T. Mestre (Chicago, USA)

  • Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC® degrader molecules as potential disease modifying therapeutics for Parkinson’s disease

    K. Kelly, J. Meredith, L. Kimmel, S. Sparks, A. Desantis, D. Bryce, R. Wilson, J. Corradi, S. Keenan, G. Cadelina, J. Pizzano, A. Cacace (New Haven, USA)

  • Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies

    A. Willuweit, M. Sevenich, G. Tamgüney, J. Mohrlüder, D. Willbold (Düsseldorf, Germany)

  • Diabetes impact on nigrostriatal vulnerability in Parkinson’s Disease

    A. Galli, A. Pilotto, C. Zatti, C. Tirloni, A. Lupini, B. Paghera, A. Padovani (Brescia, Italy)

  • Diabetic striatopathy presenting without hyperkinetic movements

    S. Bhalja, C. Sarvakar, S. Garg (Ahmedabad, India)

  • Diagnosis of Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy with 7T-MRI substantia nigra imaging

    D. Su, Z. Zhang, Z. Zhang, T. Wu, J. Jing, T. Feng (Beijing, China)

  • Diagnostic accuracy of susceptibility map-weighted MRI for discriminating tremor-dominant Parkinson’s disease and essential tremor

    MK. Yoon, S. Jo, S. Lee, J. Lee, CH. Suh, SJ. Chung (Seoul, Republic of Korea)

  • Diagnostic and treatment burden of dystonia in Turkey: a patient journey map

    R. Yilmaz, N. öksüz, B. Samancı, A. Acarer, M. Ceylan, N. Durmaz-Celik, H. Erdem, S. özkan, H. Hanağası, O. Doğu, C. Akbostancı (Ankara, Turkey)

  • Diagnostic challenges in a case of SLC6A3-related Dopamine Transporter Deficiency Syndrome

    L. Jafri, J. Martindale (Winston Salem, USA)

  • Diagnostic Utility of Blood α-Synuclein in Parkinson’s Disease: A Systematic Review and Meta-analysis

    D. Su, L. Luo, J. Lam, T. Feng (Beijing, China)

  • Diaphragmatic flutter – when the diaphragm does not obey

    M. Danis (Trnava, Slovakia)

  • Dietary protein redistribution influences the efficacy of levodopa/carbidopa intestinal gel (LCIG) infusion

    Y. Ben Mordechai, S. Israeli-Korn, O. Cohen, S. Hassin-Baer (Tel Hashomer, Israel)

  • Differences by sex in patients with Parkinson’s disease (PD) and impulse control disorder (ICD) in the Mexican population.

    A. Alcocer-Salas, M. Rodriguez-Violante, A. Cervantes-Arriaga, J. García-Hernández, A. Abundes-Corona, A. Hernández-Medrano, D. Aguila-Godinez, A. Herrera-Ruiz, E. Santiago-Delacruz, L. Lira-Juárez, M. Medrano-Delgado, M. Ruiz-Mafud, A. Regalado-Mustafá, D. Romero-Terán, M. Medina-Pérez, G. Hernandez-Armesto, A. Domínguez-García (Merida, Mexico)

  • Differences in brain activity and oscillatory responses in resting and re-emergent tremor in Parkinson’s disease

    H. Ding, B. Nasseroleslami, J. Volkmann, G. Deuschl, S. Groppa, M. Muthuraman (Würzburg, Germany)

  • Differences in EEG spectral features in Alzheimer’s and Parkinson’s disease with mild cognitive impairment

    M. Ajcevic, M. Catalan, P. Polverino, K. Iscra, G. Mazzon, C. Bertolotti, P. Manganotti (Trieste, Italy)

  • Differences in gray matter atrophy and functional connectivity between motor subtypes of Parkinson’s disease

    L. Yin, J. Fu, Z. Xu (kunming, China)

  • Differences in patients with Impulse Control Disorder based on antiparkinsonian drug treatment in a Mexican Institute.

    LG. Lira Juárez, AJ. Hernández-Medrano, MF. Medina Pérez, DP. Romero-Terán, MA. Ruiz Mafud, MAG. Medrano Delgado, AY. Regalado Mustafá, K. Talavera Lagunas, EC. Santiago Delacruz, G. Hernandez Armesto, DR. Aguila Godinez, AA. Herrera Ruiz, GI. Cerda Hernández, A. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante, A. Alcocer Salas, JF. García Hernandez, A. Domínguez García (Mexico, Mexico)

  • Differences of social and clinical factors related with distribution of DBS in Mexican PD population

    MF. Medina Pérez, DR. Aguila Godinez, AA. Herrera Ruiz, EC. Santiago Cruz, LG. Lira Juárez, MAG. Medrano Delgado, MA. Ruiz Mafud, AJ. Hernández-Medrano, AY. Regalado Mustafá, DP. Romero-Terán, GI. Cerda Hernández, M. Rodríguez-Violante, A. Cervantes-Arriaga, G. Hernandez Armesto, A. Abundes-Corona, AG. Alcocer-Salas (Mexico, Mexico)

  • Differential effect of dopaminergic medication on smooth pursuit vs. saccadic eye movements Parkinson’s disease

    M. Mlinarič, A. de Gobiss, V. Groznik, A. Sadikov, D. Georgiev (Ljubljana, Slovenia)

  • Differential effect of MAPT haplotype on survival in CBD and PSP-SCB phenotype

    A. Gharbi, I. Sghaier, I. Kacem, S. Mrabet, A. Souissi, A. Gargouri, A. Nasri, R. Gouider (Tunis, Tunisia)

  • Differential Rab10 & Rab8A phosphorylation by LRRK2 variants G2019S & I1371V manifests differences in membrane fluidity & pathogenicity.

    KH. Singh, IND. Datta (Bengaluru, India)

  • Differential Spatiotemporal Gait Effects with Frequency and Dopaminergic Modulation in STN-DBS

    R. Ramdhani, J. Watts, M. Klein, T. Fitzpatrick, M. Niethammer, A. Khojandi (Great Neck, USA)

  • Diffuse cerebellar edema in acute anti-Yo positive paraneoplastic cerebellar degeneration: A case report

    T. Dang, K. Vo, U. Ha, Q. Pham, C. Phan, T. Tran (HO CHI MINH, Viet Nam)

  • Diffusion imaging study of mild behavioral impairment in Parkinson’s disease.

    H. Almgren, M. Descoteaux, M. Ghahremani, Z. Ismail, O. Monchi (Calgary, Canada)

  • Diffusion Tensor Imaging in GBA-related Parkinson’s disease

    R. Dayan, A. Bick, C. Muller, N. Levin, D. Arkadir (Jerusalem, Israel)

  • Diffusion Tensor Imaging of Spinocerebellar ataxia type 12 patients in comparison of Healthy control

    AK. Srivastava, P. Pankaj, S. Kumaran, A. Garg, R. Agarwal, A. Nehra, F. Mohammad (New Delhi, India)

  • Digital gait and turning impairments (quality but not quantity) during daily life are more severe in retrospective fallers compared to non-fallers with Parkinson’s disease

    V. Shah, C. Silva-Batista, P. Burgos, A. Ragothaman, P. Carlson-Kuhta, K. Sowalsky, F. Horak, M. Mancini (Porltand, USA)

  • Digital mobility sub-study in the Parkinson’s Progressive Marker Initiative (PPMI) study.

    A. Mirelman, T. Simuni, C. Tanner, E. Flagg, A. Lorenzo, J. Dimos, C. Coffey, A. Siderowf, K. Marek (Tel Aviv, Israel)

  • Diplopia (Double vision) in Parkinson’s disease patients: prevalence and nonmotor effect

    EL. Ungureanu, KR. Chaudhuri, ș. Diaconu, L. Irincu, R. Filip, B. Ciopleiaș, C. Falup-Pecurariu (Brasov, Romania)

  • Directional deep brain stimulation therapy in the long term

    E. Sanesteban Beceiro, A. Fernández Revuelta, E. López Valdés, R. García-Ramos, C. Fernández García, F. Alonso Frech (Madrid, Spain)

  • Discriminative properties and sensitivity to change of three cognitive assessment instruments in Huntington’s disease

    A. Horta-Barba, S. Martinez-Horta, J. Pérez-Pérez, A. Puig-Davi, N. de Lucia, G. de Michele, E. Salvatore, S. Kehrer, J. Priller, S. Migliore, F. Squitieri, A. Castaldo, C. Mariotti, V. Mañanes, J. Lopez-Sendon, N. Rodriguez, A. Martinez-Descals, F. Júlio, C. Januário, M. Delussi, M. de Tommaso, S. Noguera, J. Ruiz-Idiago, E. J. Sitek, R. Wallner, A. Nuzzi, J. Pagonabarraga, J. Kulisevsky, HD. Disease Network (BARCELONA, Spain)

  • Disease progression in multiple system atrophy: the value of clinical cohorts with long follow-up

    T. Saulnier, M. Fabbri, A. Pavy-Le Traon, M. Le Goff, C. Helmer, P. Péran, WG. Meissner, O. Rascol, C. Proust-Lima, A. Foubert-Samier (Bordeaux, France)

  • Disease progression in Parkinson‘s disease patients with Mild Cognitive Impairment: 5-year longitudinal study from The Early Parkinson’s disease Longitudinal Singapore (PALS) cohort

    X. Deng, S. Saffari, S. Ng, N. Chia, X. Choi, D. Heng, B. Xiao, Z. Xu, K. Tay, W. Au, N. Liu, E. Tan, L. Tan (Singapore, Singapore)

  • Disease progression of data-driven subtypes of Parkinson Disease (PD): 5-year longitudinal study from The Early Parkinson’s disease Longitudinal Singapore (PALS) cohort

    X. Deng, ES. Saffari, SN. Ng, NC. Chia, XY. Choi, D. Heng, XB. Xiao, Z. Xu, K. Tay, W. Au, N. Liu, EK. Tan, LT. Tan (Singapore, Singapore)

  • Disease progression of spinocerebellar ataxia types 1, 2, 3, and 6 before and after ataxia onset: a joint analysis of two longitudinal cohort studies

    H. Jacobi, T. Schaprian, M. Schmid, T. Klockgether (Heidelberg, Germany)

  • Disorder of bulk lipid transfer? Lipid composition and distribution in cellular models of VPS13A disease

    K. Peikert, A. Spranger, E. Fischer, H. Glaß, B. Falkenburger, G. Miltenberger-Miltenyi, D. Tyteca, C. Klose, D. Grossmann, A. Hermann (Rostock, Germany)

  • Disruption of Locus Coeruleus-Related Functional Networks in Parkinson’s Disease

    J. Sun, J. Ma, L. Gao, J. Wang, D. Zhang, L. Chen, J. Fang, T. Feng, T. Wu (Beijing, China)

  • Distinct characteristics of gut microbiome in patients with Parkinson’s disease according to the presence of premotor REM sleep behavior disorders

    S. Jo, JY. Lee, JW. Bae, SJ. Chung (Seoul, Republic of Korea)

  • Distinct deep grey matter iron accumulation in tremoric syndromes; an apparent quantitative susceptibility mapping mangetic resonance study

    A. Martín-Bastida, I. Aviles-Olmos, A. Gorospe-Osinalde, V. Suarez-Vega, P. Dominguez-Echavarri, R. García-Eulate, C. Sánchez-Catasús, MC. Rodríguez-Oroz (Pamplona, Spain)

  • Distinct striatal connectivity patterns in patients with Parkinson’s disease with and without urinary symptoms

    N. Piramide, R. de Micco, F. Di Nardo, M. Siciliano, G. Caiazzo, G. Tedeschi, F. Esposito, A. Tessitore (Napoli, Italy)

  • Distinct temporal and spatial alteration of immunoproteasome in Parkinson’s Disease pathogenesis

    HD. Nguyen, YE. Kim, TT. Lai, HN. Pham, IH. Kwak, H. Ma (Anyang, Gyeonggi-do, Republic of Korea)

  • DNA Methylation is associated with gene expression changes in sporadic Parkinson Disease in the PPMI cohort.

    P. Gonzalez-Latapi, B. Bustos, T. Simuni, S. Lubbe, D. Krainc (Chicago, USA)

  • DNAJC12 defect a new neurodevelopmental disorder associated with parkinsonism-dystonia

    F. Manti, G. Ricciardi, L. Pollini, C. Artiola, C. Carducci, MT. Carbone, D. Mei, F. Porta, A. Burlina, R. Guerrini, V. Leuzzi (Roma, Italy)

  • Does baseline expectation of benefit predict outcome in SURE-PD3, a Randomized, Double-Blind, Placebo-Controlled, Phase III trial of Inosine in Parkinson’s disease?

    T. Mestre, E. Macklin, A. Lang, M. Schwarzschild (Ottawa, Canada)

  • Does beta band activity correlate with electrode location within the STN in postoperative processed images?

    M. Ruiz-Lopez, B. Tijero, T. Fernandez, G. Bilbao, JC. Gomez-Esteban, E. Ruiz Degopegui (Bilbao, Spain)

  • Does Cognitive Complaint in Parkinson’s Disease Reflect in Neuropsychological Testing?

    C. Catiul, S. Lopez, V. Mishra (Birmingham, USA)

  • Does fatigue in Parkinson’s disease impact one’s physical function in daily live?

    B. Lindholm, E. Franzen (Malmö, Sweden)

  • Does hyposmia induce apathy in early Parkinson’s disease? Lessons from structural brain connectivity

    A. Martinez-Nunez, H. Soltanian-Zadeh, K. Latack, N. Ghazi, A. Mahajan (Detroit, USA)

  • Does sex affect worsening of cognitive and IADL functions in PD with and without PD-MCI?

    I. Liepelt-Scarfone, M. Bode, S. Solbrig, K. Brockmann, W. Maetzler, I. Wurster, M. Timmers, D. Berg, S. Becker (Tübingen, Germany)

  • Does sleep disorder affect cognitive impairment in Parkinson’s disease?

    M. Miyashita, K. Hasegawa, M. Sagawa, A. Kumon (kanagawa, Japan)

  • Does the dopaminergic pathway interfere with the sustained CSF tap test effect in normal-pressure hydrocephalus?

    H. Onder, T. Comoglu, S. Comoglu (Ankara, Turkey)

  • Dopamine depletion of striatal subregions and motor dysfunction in prodromal and clinical Parkinson’s disease

    M. Banwinkler, M. Hoenig, V. Dzialas, T. van Eimeren (Cologne, Germany)

  • Dopamine dysfunction in nigro-striatal pathway—multi-axial pathology in SCA 12

    P. Basu, J. Ganguly, S. Pandey, S. Mukherjee, N. Singh, S. Choudhury, H. Kumar (Kolkata, India)

  • Dopamine dysregulation syndrome in Parkinson’s disease controlled by safinamine

    SK. Song, JH. Kang (Jeju-Si, Republic of Korea)

  • Dopamine Receptor Gene Polymorphism in L-Dopa Induced Dyskinesia- A Study from Eastern India

    S. Sarkar, S. Choudhury, S. Ansari, R. Banerjee, S. Dey, H. Kumar (Kolkata, India)

  • Dopamine transporter in the brain is linked to irritable bowel syndrome in Parkinson´s disease

    K. Murtomäki, J. Joutsa, T. Mertsalmi, E. Jaakkola, E. Mäkinen, R. Levo, M. Eklund, S. Nuuttila, E. Pekkonen, T. Noponen, T. Ihalainen, V. Kaasinen, F. Scheperjans (Helsinki, Finland)

  • Dopamine-responsive x-linked parkinsonism-epilepsy due to phosphoglycerate kinase-1 deficiency

    J. Parmera, T. Guimarães, R. Cury, F. Freua, E. Barbosa, F. Kok (São Paulo, Brazil)

  • Dopaminergic Neuronal attributes in aging Substantia Nigra and Ventral Tegmental Area of mice strains distinctly sensitive to MPTP

    S. Choudhury, P L. Abhilash, P. Alladi (Bengaluru, India)

  • Dopaminergic neuronal cell therapy for Parkinson’s Disease: results from a phase 1 study of Bemdaneprocel

    C. Henchcliffe, H. Sarva, A. Lozano, A. Fasano, S. Kalia, C. Brennan, K. Yu, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (Orange, USA)

  • Double lesion magnetic resonance-guided focused ultrasound treatment for cervical dystonia: a pilot study of two targets combination based on clinical symptoms

    R. Galimova, Y. Sidorova, I. Buzaev, S. Illarioshkin, S. Safin, G. Akhmadeeva, D. Nabiullina, D. Teregulova, D. Krekotin, K. Meshchanova (Ufa, Russian Federation)

  • Double trouble: dystonic tremor due to FXTAS in a SCA1 family

    P. Santurelli, G. Bonato, R. Polli, A. Murgia, M. Carecchio (Padova, Italy)

  • Double-blind, randomized, crossover clinical trial to compare VIM vs PSA deep brain stimulation in patients with disabling essential tremor. Preliminary results.

    L. Triguero-Cueva, CJ. Madrid Navarro, MJ. Perez Navarro, B. Iáñez Velasco, M. Jouma Katati, JP. Martínez Barbero, A. Mínguez-Castellanos, F. Escamilla Sevilla (Jódar, Spain)

  • Drivers of Health-Related Quality of Life in Parkinson’s Disease: non-motor symptoms and time spent in daily activities

    C. Painous, I. Pijuan, E. Tolosa (Barcelona, Catalonia)

  • Drivers of longitudinal healthcare cost in Parkinson Disease

    S. Neo, SW. Goh, ES. Saffari, AB. Zhan, HL. Ng, W. Li, R. Hoe, Z. Xu, KY. Tay, WL. Au, LCS. Tan (Singapore, Singapore)

  • Drooling is associated with disease severity in Parkinson’s disease

    N. Nishikawa, E. Ikami, H. Takeshige, T. Ogawa, T. Hatano, N. Hattori (Tokyo, Japan)

  • Drug-induced Parkinsonism and nonmotor symptoms: a case of gustatory rhinorrhea

    S. Casanova, A. Cabral, M. Branco (Vila Nova Gaia, Portugal)

  • Dry Cleaning Chemicals and Parkinson’s Disease

    M. Pawlik, S. Lettenberger, M. Zafar, P. Auinger, K. Hylton, M. Coffey, S. Goldman, B. de Miranda, K. Kieburtz, H. Schwarz, R. Barbano, M. Braun, J. Adams, D. Kinel, R. Dorsey (Rochester, USA)

  • Dual globus pallidus internus and subthalamic nucleus deep brain stimulation for medically refractory craniocervical dystonia: a case report

    C. Swan, S. Sani, N. Patel (Chicago, USA)

  • Dynamic assessment of levels of depression and anxiety impairment in Parkinson’s disease

    O. Naimov, R. Matmurodov (Tashkent, Uzbekistan)

  • Dysconnectivity of the Parafascicular Nucleus in Parkinson’s Disease

    L. Chen, T. Wu (Beijing, China)

  • Dysconnectivity Profiles of Raphe Nuclei in Parkinson’s Disease: From Prodromal to Advanced Stage

    W. Junling, S. Junyan, Z. Dongling, C. Lili, W. Tao (Beijing, China)

  • Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study

    P. Lorenzo-Barreto, I. Pareés, P. Pérez-Torre, S. Fanjul, JL. López-Sendón, F. Pérez-Trapote, A. Sáez-Marín, E. Stiauren-Fernández, á. Patiño-Patón, JC. Martínez-Castrillo, A. Alonso-Cánovas (Madrid, Spain)

  • Dysphagia and dopaminergic neurodegeneration in Parkinson’s Disease

    S. Polychronis, B. Ribba, G. Nasios, E. Dardiotis, G. Pagano (Ioannina, Greece)

  • Dysphagia in Parkinson’s disease

    M. Carmona-Abellan, A. Ibargutxi, E. Gómez, N. Zuza, B. Díez-Arrola, K. Berganzo, C. Garcia-Monco, J. Zabala, A. Bilbao, U. Pequeño (Bilbao, Spain)

  • Dyspnea and quality of life in Parkinson’s: a mixed methods study

    M. Darabseh, A. Aburub (Amman, Jordan)

  • Dystonia and women: impact on reproductive life, life satisfaction and psychosocial factors

    G. Cabañas Engenios, N. Mena García, R. Pastor González, M. Campos Jiménez, A. Patiño Patón, M. López Morales, E. Pulido Sánchez, R. Berbegal Serralta, S. Lozano Veiga, E. Cañada Lahoz, E. Casas Peña, A. Alonso Cánovas (Madrid, Spain)

  • Dystonia as presenting feature of Witteveen-kolk Syndrome

    F. Mustafa, K. Sai Krishna, D. Vibha, R K. Singh, M. Tripati, A. Elavarsi, S. Gaikwad, B. Mishra (NEW DELHI, India)

  • dystonia caused by a rare variant of TUBB4A gene: a case report in a non-asian population

    R. Ferreira, N. Frota, JI. Landim, M. Bessa, P. Matos, D. Rangel, F. Carvalho (Fortaleza, Brazil)

  • Dystonia in the Middle East – The Cleveland Clinic Abu Dhabi Experience

    S. Mansoor, K. Waqar, M. Thomas, S. Mittal (Abu Dhabi, United Arab Emirates)

  • Dystonia Treatment With Injections Supplemented by TMS: the D-TWIST Study

    J. Frey, J. Yu, J. Lobo Lopes, L. Fanty, I. Malaty, A. Ramirez-Zamora, M. Wajid, J. Cagle, C. de Hemptinne, A. Wagle Shukla (Morgantown, USA)

  • Dystonic tremor as main manifestation of a large SCA21 family

    V. Yahya, E. Monfrini, E. Moro, A. Di Fonzo (Milan, Italy)

  • DYT1 gene mutation: an atypical presentation with myoclonic dystonia

    G. Belluscio, F. Valentino, G. Cosentino, S. Gana, R. Zangaglia, C. Pacchetti (Pavia, Italy)

Jump to:  View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley